153 results
6-K
EX-99.1
BLU
Bellus Health Inc
7 Dec 20
Bellus Health Inc. 6-K
7:01am
. “Ramzi’s extensive experience developing corporate strategy for clinical-stage and commercial biopharma companies, combined with his proven track … of increasing responsibilities spanning from R&D and global finance to strategy and operations at Merck, Johnson & Johnson, Shire Plc. and Purdue Pharma
6-K
EX-99.1
BLU
Bellus Health Inc
25 Feb 21
BELLUS Health Reports Year 2020 Financial Results and Business Highlights
4:02pm
significant progress with our corporate strategy, financial position, and clinical development of BLU-5937 – laying the groundwork for what we anticipate … Officer. Mr. Benamar brings to the Company extensive experience in corporate strategy, finance and operations.
FINANCIAL RESULTS
Cash Position
F-10
EX-4.3
BLU
Bellus Health Inc
20 Aug 03
Registration of securities (Canada)
12:00am
approaches to disease therapy. A key element to the Corporation's strategy is an
understanding of the mechanisms underlying the pathology associated …
AMYLOID APPROACH
Aside from the Corporation's amyloid approach, another therapeutic amyloid
strategy is to develop secretase inhibitors which will limit
6-K
EX-99.1
BLU
Bellus Health Inc
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
to: the benefits and impact on label of its enrichment strategy, e sti mates and projections regarding the size and opportunity of the addressable RCC market … 24H cough frequency (CF) in enriched population 19
CALM Program: Enrichment Strategy 20 CALM - 1 and CALM - 2 populations to be enriched
40-F
2004 FY
EX-1
BLU
Bellus Health Inc
13 May 04
Annual report (Canada)
12:00am
$500,000 in a
private placement concluded by Innodia. As at June 30, 2003, we indirectly owned
a 31% equity interest in Innodia. This strategy … and
commercialization of innovative therapeutics for neurological disorders. Our
strategy is to in-license early-stage products and to focus our resources
6-K
EX-99.1
zloul3dw 4ozoyfbbt9
12 Nov 20
BELLUS Health Reports Third Quarter 2020 Financial Results and Business Highlights
7:01am
6-K
EX-99.1
22ri2t2r76zhed2 mrp5
24 Mar 21
BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors
7:00am
6-K
EX-99.2
83ia6wlm6 dy
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
F-10
EX-4.2
r07so66kbfpq5h
23 Feb 05
Registration of securities (Canada)
12:00am
6-K
EX-99.2
ckov3519a00r8a
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
dxvz29m0 8r
8 Sep 20
BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough
7:00am
6-K
9m6iiqa 7s
16 Apr 08
Current report (foreign)
12:00am
6-K
oa19b
11 Dec 03
Current report (foreign)
12:00am
6-K
EX-99.1
avuq5ma
10 Nov 21
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
4:30pm
6-K
EX-99.2
w6ut2rn9
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
u5oe m21te
3 Nov 05
Current report (foreign)
12:00am
6-K
iulsj
4 Jan 07
Current report (foreign)
12:00am
6-K
EX-99.1
amibetix
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
htojb0xcoip
5 Jul 22
BELLUS Health to Participate in the William Blair Biotech Focus Conference
7:00am
6-K
1yelxd
11 Feb 08
Current report (foreign)
12:00am